Literature DB >> 20138087

Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity.

Youssef Gali1, Kevin K Ariën, Marleen Praet, Rafael Van den Bergh, Marleen Temmerman, Olivier Delezay, Guido Vanham.   

Abstract

Heterosexual transmission of human immunodeficiency virus (HIV-1) is the predominant mode of infection worldwide. However, the early steps of transepithelial infection still need to be clarified. Using epithelial cells, originating from the female genital tract, and peripheral blood mononuclear cells as subepithelial target cells, an in vitro dual-chamber model of the female genital tract was developed. Remarkably, an intact layer of some cell types (HEC-1A, CaSki and Ect1) served as a protective barrier against cell-free but not against cell-associated HIV-1 that crossed the epithelial barrier through transmigration. Furthermore, dysfunctions of the epithelial layers were assessed by monitoring transepithelial electric resistance and transepithelial passage of FluoSpheres and HIV-1 after treatment with nonoxynol-9 (N-9). Most of the functional assays showed dysfunction of the epithelial barrier at lower concentrations compared to a widely used colorimetric toxicity assay (WST-1). Finally, N-9 treatment caused a significant increase in the production of interleukin-8 (IL-8) and macrophage inflammatory protein-3alpha (MIP-3alpha) and a decrease of Secretory Leukocyte Protease Inhibitor (SLPI) and Monocyte Chemotactic Protein-1 (MCP-1) in this model. In conclusion, this model is a useful tool to (1) study HIV-1 transmission mechanisms and (2) evaluate epithelial toxicity of candidate microbicides. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138087     DOI: 10.1016/j.jviromet.2010.01.018

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  15 in total

1.  In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.

Authors:  Youssef Gali; Olivier Delezay; Joachim Brouwers; Noura Addad; Patrick Augustijns; Thomas Bourlet; Hind Hamzeh-Cognasse; Kevin K Ariën; Bruno Pozzetto; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.

Authors:  José das Neves; Johan Michiels; Kevin K Ariën; Guido Vanham; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Pharm Res       Date:  2011-11-10       Impact factor: 4.200

3.  In vitro activities of candidate microbicides against cell-associated HIV.

Authors:  Philippe Selhorst; Katrijn Grupping; Thomas Bourlet; Olivier Delézay; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

4.  Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides.

Authors:  H Irene Su; Courtney A Schreiber; Courtney Fay; Sam Parry; Michal A Elovitz; Jian Zhang; Alka Shaunik; Kurt Barnhart
Journal:  Contraception       Date:  2011-03-29       Impact factor: 3.375

5.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

6.  Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor.

Authors:  Wei Zhang; Michael A Parniak; Stefan G Sarafianos; Marilyn R Cost; Lisa C Rohan
Journal:  Int J Pharm       Date:  2013-12-09       Impact factor: 5.875

7.  Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma.

Authors:  R Bücker; C Schaefer; A D Gruber; J Hoppe; L Lazzerini; J Barinoff; J Sehouli; Günter Cichon
Journal:  Pharm Res       Date:  2018-11-08       Impact factor: 4.200

8.  Development of an in vitro alternative assay method for vaginal irritation.

Authors:  Seyoum Ayehunie; Chris Cannon; Karen Larosa; Jeffrey Pudney; Deborah J Anderson; Mitchell Klausner
Journal:  Toxicology       Date:  2010-10-17       Impact factor: 4.221

9.  Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Dror Kolodkin-Gal; Sandrine L Hulot; Birgit Korioth-Schmitz; Randi B Gombos; Yi Zheng; Joshua Owuor; Michelle A Lifton; Christian Ayeni; Robert M Najarian; Wendy W Yeh; Mohammed Asmal; Gideon Zamir; Norman L Letvin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

10.  Impact of Hydroxychloroquine-Loaded Polyurethane Intravaginal Rings on Lactobacilli.

Authors:  Yannick Leandre Traore; Yufei Chen; Anne-Marie Bernier; Emmanuel A Ho
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.